^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Ilaris (canakinumab)

i
Other names: ACZ885, ACZ-885, antibody A
Associations
Company:
Novartis
Drug class:
IL-1β inhibitor
Associations
20d
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. (PubMed, BMC Cancer)
The combination of spartalizumab and PDC, with or without canakinumab, was well tolerated across treatment groups. The antitumor activity across treatment groups was comparable with that of pembrolizumab and pemetrexed combination. Canakinumab did not appear to improve the antitumor activity when combined with spartalizumab, pemetrexed and cisplatin.
Journal • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • spartalizumab (PDR001) • Ilaris (canakinumab)
1m
Adult-onset Still's disease masquerading as acute coronary syndrome: a case report and review of the literature. (PubMed, J Med Case Rep)
Adult-onset Still's disease should be considered in the differential diagnoses of fever of undetermined origin. Early identification and initiation of treatment are critical to faster recovery and prevention of progression to severe complications. Steroids remain the standard first-line therapy and should be followed by disease-modifying steroid sparing drugs. The social determinants of health may preclude their timely initiation and should alert providers of proactive ways to avoid further delays.
Review • Journal
|
IL6 (Interleukin 6)
|
Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kineret (anakinra)
2ms
Enrollment open
|
Ilaris (canakinumab)
2ms
Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. (PubMed, Cochrane Database Syst Rev)
This Cochrane review assessed the benefits and harms of using interleukin-receptor antagonists and tumour necrosis factor inhibitors for primary and secondary prevention of atherosclerotic diseases compared with placebo or usual care. However, the evidence for the predetermined outcomes was deemed low or very low certainty, so there is still a need to determine whether these interventions provide clinical benefits or cause harm from this perspective. In summary, the different biases and imprecision in the included studies limit their external validity and represent a limitation to determining the effectiveness of the intervention for both primary and secondary prevention of ACVD.
Clinical • Review • Journal
|
IL6R (Interleukin 6 receptor)
|
Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kineret (anakinra)
3ms
Trial termination
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
4ms
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2024 --> Aug 2025
Trial completion date
|
Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
4ms
Evaluation of Canakinumab in High-Risk Former-Smokers (clinicaltrials.gov)
P2, N=75, Recruiting, Peter Shields | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Mar 2024
Enrollment open • Trial initiation date
|
IL1B (Interleukin 1, beta) • CASP1 (Caspase 1)
|
Ilaris (canakinumab)
4ms
Trial completion
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
4ms
The Multifaceted Complexity of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS): A Case Report Highlighting Atypical Gastrointestinal Manifestations. (PubMed, Diagnostics (Basel))
This case report emphasizes the diverse manifestations of TRAPS and the importance of recognizing gastrointestinal complications, particularly isolated colic amyloidosis. Comprehensive evaluation, including histological examination, is crucial for identifying atypical disease presentations and guiding management decisions. Continued research is needed to elucidate the underlying mechanisms and optimize treatment strategies for TRAPS and its associated complications.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
|
Ilaris (canakinumab) • Kineret (anakinra)
4ms
Blockade of IL-1β and PD-1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor. (PubMed, Cancer Immunol Res)
Patients with treatment-naïve advanced pancreatic ductal adenocarcinoma (n=10) were treated with canakinumab, a high-affinity monoclonal human anti-interleukin-1β (IL-1β), the PD-1 blocking antibody spartalizumab, and gemcitabine/n(ab)paclitaxel. Within the tumor we observed few changes in suppressive myeloid-cell populations or activated T cells as assessed by single-cell transcriptional profiling or multiplex immunofluorescence, although increases in CD8+ T cells suggest that improvements in the tumor immune microenvironment might be revealed by a larger study. Overall, the data indicate that exposure to PD-1 and IL-1β blockade induced a modest reactivation of peripheral CD8+ T cells and decreased circulating monocytic MDSCs; however, these changes did not lead to similarly uniform alterations in the tumor microenvironment.
Journal • Metastases
|
CD8 (cluster of differentiation 8) • IL1B (Interleukin 1, beta)
|
gemcitabine • paclitaxel • spartalizumab (PDR001) • Ilaris (canakinumab)
4ms
New P3 trial
|
Ilaris (canakinumab)
4ms
CanpHy: Canakinumab for the Treatment of Postprandial Hypoglycemia (clinicaltrials.gov)
P3, N=56, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
Trial completion date • Trial primary completion date
|
Ilaris (canakinumab)
5ms
New P1 trial
|
Ilaris (canakinumab)
5ms
POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov)
P=N/A, N=5000, Recruiting, Duke University | Trial completion date: Jul 2024 --> Sep 2027 | Trial primary completion date: May 2024 --> Sep 2026
Trial completion date • Trial primary completion date
|
metformin • Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kevzara (sarilumab) • Kineret (anakinra)
5ms
Challenges and advances in the management of inflammation in atherosclerosis. (PubMed, J Adv Res)
This review explores cutting-edge anti-inflammatory interventions, their potential efficacy in preventing and alleviating atherosclerosis, and the role of nanotechnology in delivering drugs more effectively and safely.
Review • Journal
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL6R (Interleukin 6 receptor) • IL1B (Interleukin 1, beta)
|
Ilaris (canakinumab)
5ms
CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date • Metastases
|
cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
5ms
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials? (PubMed, Cancer Prev Res (Phila))
In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the TET2 gene, predict a benefit of decreased cancer risk with the administration of the anti-IL1β agent canakinumab...Such personalized approaches can potentially enhance the feasibility of cancer prevention trials. See related article by Woo et al., p. XX (2).
Journal
|
TET2 (Tet Methylcytosine Dioxygenase 2) • IL1B (Interleukin 1, beta)
|
Ilaris (canakinumab)
6ms
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS (clinicaltrials.gov)
P1, N=33, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business reasons
Trial termination
|
sabatolimab (MBG453) • Ilaris (canakinumab) • nisevokitug (NIS793)
6ms
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients (clinicaltrials.gov)
P2, N=10, Terminated, University of Leipzig | It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
Ilaris (canakinumab)
7ms
Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial. (PubMed, Cancer Prev Res (Phila))
The cumulative incidence of at least one reported malignancy was lower for patients with TET2 mutations treated with canakinumab vs those treated with placebo. These findings support a potential role for canakinumab in cancer prevention and provide evidence of IL-1β blockade cooperating with CH mutations to modify the disease course.
Clinical • Journal
|
DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • IL1B (Interleukin 1, beta)
|
DNMT3A mutation • TET2 mutation
|
Ilaris (canakinumab)
7ms
Unlocking therapeutic potential: IL-1β as a target in non-small cell lung cancer with oncogenic mutations—Prognostic and predictive insights. (ASCO 2024)
The phase II CANTOS trial incidentally showed reduced lung cancer incidence and mortality with the IL-1β inhibitor canakinumab... Our study shows promising prognostic value of IL-1β expression in NSCLC, associating low expression with improved OS across NSCLC subtypes. IL-1β expression is closely linked to key driver mutations in NSCLC and may have predictive value for ICIs. The findings suggest the potential benefit of targeting IL-1β in high IL-1β expressing NSCLC with driver mutations.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • IL1B (Interleukin 1, beta)
|
MI Tumor Seek™
|
Ilaris (canakinumab)
7ms
Enrollment closed • Enrollment change
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
7ms
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease (clinicaltrials.gov)
P2, N=34, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Terminated by sponsor
Trial termination
|
Ilaris (canakinumab)
7ms
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009-2022: an interim analysis using the French JIR cohort database. (PubMed, Arthritis Res Ther)
This interim analysis showed a good maintenance of canakinumab treatment 2 years after initiation and confirmed its safety profile in real-life practice in France in patients diagnosed with FMF, MKD and TRAPS. The high variety of dose and interval combinations observed in canakinumab treated patients let suppose that physicians adapt the posology to individual situations rather than a fixed treatment plan.
Journal • HEOR • Real-world evidence • Real-world
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Ilaris (canakinumab)
7ms
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
Trial completion date • Trial primary completion date
|
Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
9ms
Identifying functional dysregulation of NOD2 variant Q902K in patients with Yao syndrome. (PubMed, Arthritis Res Ther)
Overproduction of pro-inflammatory cytokines and the hyperactivation of NOD2-mediated signaling pathways were found in the NOD2 variant Q902K patient with YAOS. NOD2-RIP2-MAPK pathway might play a pivotal role in the pathogenesis of YAOS. These results provide new perspectives for targeted therapies in YAOS.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta)
|
Ilaris (canakinumab)
9ms
Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry. (PubMed, RMD Open)
Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS.
Journal
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
9ms
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1b/2 --> P1/2
Phase classification
|
Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
9ms
Clinical • P3 data • Journal • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
docetaxel • Ilaris (canakinumab)
10ms
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Ilaris (canakinumab)
10ms
C-reactive protein, cardiovascular issues of an acute-phase protein: an update for theclinician (PubMed, Arch Cardiol Mex)
However, the variations in CRP levels, that depend on sex, ethnicity, hormonal status, and some peculiarities of the measurement assays, must be taken into consideration when deciding to implement CRP as a useful biomarker in the study and treatment of atherosclerotic cardiovascular disease. This review aims to offer an updated vision of the importance of measuring CRP levels as a biomarker of cardiovascular risk beyond the traditional factors that estimate the risk of atherosclerotic disease.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
Ilaris (canakinumab)
10ms
Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey. (PubMed, Arthritis Rheumatol)
This study provides one of the largest epidemiologic datasets for CAPS. While early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS following canakinumab treatment.
Journal • Real-world evidence • Real-world effectiveness • Real-world
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Ilaris (canakinumab)
10ms
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov)
P2, N=138, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2025 --> Jun 2024 | Trial primary completion date: Oct 2025 --> Jun 2024
Trial completion date • Trial primary completion date
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
10ms
Hegemony of inflammation in atherosclerosis and coronary artery disease. (PubMed, Eur J Pharmacol)
Cholesterol-inflammation lowering agents (statins), monoclonal antibodies targeting IL-1 and IL-6 (canakinumab and tocilizumab), disease-modifying antirheumatic drugs (methotrexate), sodium-glucose transport protein-2 (SGLT2) inhibitors, colchicine and xanthene oxidase inhibitor (allopurinol) have shown promising results in reducing inflammation, regressing atherogenic plaque and modifying the course of CAD. Here, we review the complex interplay between inflammatory, endothelial, smooth muscle and foam cells. Moreover, the putative role of inflammation in atherosclerotic CAD, underlying mechanisms and potential therapeutic implications are also discussed herein.
Review • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
methotrexate • Actemra IV (tocilizumab) • Ilaris (canakinumab)
11ms
Intestinal Behçet's and suspected intestinal Behçet's disease: a report of four surgical cases. (PubMed, Surg Case Rep)
Intestinal BD may flare up after surgical treatment and require multiple surgeries. Introducing pharmacotherapy as soon as possible after surgical treatment is important to control the disease.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
Ilaris (canakinumab)
11ms
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)
11ms
Clinical Presentation of Schnitzler's Syndrome: A Rare Autoimmune Disease. (PubMed, J Investig Med High Impact Case Rep)
The patient was ultimately treated with canakinumab (Il-1 inhibitor), with near resolution of symptoms. This case demonstrates the importance of a broad differential diagnosis and maintaining a high clinical suspicion for rare diseases when presented with a complex form of an otherwise common condition.
Journal
|
CRP (C-reactive protein)
|
Ilaris (canakinumab)
12ms
Clinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • IL6 (Interleukin 6) • CRP (C-reactive protein)
|
ALK mutation
|
Keytruda (pembrolizumab) • Ilaris (canakinumab)
12ms
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study. (PubMed, Front Med (Lausanne))
The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D syndrome, and cryopyrin-associated periodic syndrome, but this treatment has not been assessed for patients with undifferentiated AIDs (uAIDs)...Initial treatment before canakinumab consisted of non-biologic therapies: non-steroidal anti-inflammatory drugs (NSAID) (91%), corticosteroids (88%), methotrexate (38%), intravenous immunoglobulin (IVIG) (34%), cyclosporine A (25%), colchicine (6%) cyclophosphamide (6%), sulfasalazine (3%), mycophenolate mofetil (3%), hydroxychloroquine (3%), and biologic drugs: tocilizumab (62%), sarilumab, etanercept, adalimumab, rituximab, and infliximab (all 3%)...The treatment of patients with uAIDs using canakinumab was safe and effective. Further randomized clinical trials are required to confirm the efficacy and safety.
Clinical • Retrospective data • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • PLCG2 (Phospholipase C Gamma 2) • TNFAIP3 (TNF Alpha Induced Protein 3) • IL10 (Interleukin 10) • IFIH1 (Interferon Induced With Helicase C Domain 1) • PRF1 (Perforin 1) • STAT2 (Signal transducer and activator of transcription 2) • TNFRSF11A (TNF Receptor Superfamily Member 11a) • DDX58 (DExD/H-Box Helicase 58) • PSMB8 (Proteasome 20S Subunit Beta 8) • STAT4 (Signal Transducer And Activator Of Transcription 4) • STXBP2 (Syntaxin Binding Protein 2) • TNFRSF1B (TNF Receptor Superfamily Member 1B)
|
Rituxan (rituximab) • cyclophosphamide • hydroxychloroquine • Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kineret (anakinra)
1year
COVER: COVID-19 VaccinE Response in Rheumatology Patients (clinicaltrials.gov)
P4, N=1000, Recruiting, Jeffrey Curtis | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: May 2023 --> Feb 2024
Trial completion date • Trial primary completion date • Immunomodulating
|
tofacitinib • Cosentyx (secukinumab) • Ilaris (canakinumab)
1year
Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA) (ASH 2023)
Additionally, 33% and 56% were refractory to lenalidomide and luspatercept therapy, respectively. The combination of canakinumab and darbepoetin was safe and well tolerated and 300mg of canakinumab is the RP2D. Canakinumab inhibited inflammasome activation as evidenced by a reduction of ASC specks although this did not translate to clinical responses. Phase 2 of the study will focus on patients with lower transfusion burden and molecular subsets with highest IL-1β expression (e.g.
Clinical • P1/2 data
|
DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • IL1B (Interleukin 1, beta) • CASP1 (Caspase 1)
|
DNMT3A mutation • TET2 mutation
|
lenalidomide • Reblozyl (luspatercept-aamt) • Aranesp (darbepoetin alfa) • Ilaris (canakinumab)